According to the research report titled ‘U.S. Non-Invasive Prenatal Testing Market - Growth, Demand, Trends, Opportunity, Forecasts (2020 - 2027)’, available with MarketStudyReport, U.S. non-invasive prenatal testing market is anticipated to surpass USD 2.2 billion by the end of forecast period 2021-2027, registering a CAGR of 18% by the end of forecast period.
 

U.S. non-invasive prenatal testing market growth is primarily driven by potential chromosomal abnormalities risk with increase in maternal age, rising cases of fetal chromosomal aneuploidies, and development of advanced non-invasive prenatal testing products.
 

Request sample copy of this report: https://www.marketstudyreport.com/request-a-sample/2915595/
 

Rising inclination towards non-invasive techniques in comparison to invasive methods, growing emphasis on reimbursement for NIPT, ACOG guidelines recommendations for NIPT for all pregnancies irrespective of risk, and rising cognizance of prenatal testing are also contributing to the overall market growth.
 

Prenatal testing has shifted to non-invasive technologies for determining the embryonic risk of genetic diseases without causing miscarriage. New screening methods for fetal chromosomal aneuploidies have emerged as a result of advances in modern molecular technologies and the identification of cell-free fetal DNA in maternal plasma.
 

U.S. non-invasive prenatal testing industry is expected to witness significant technological advancements. Several well-known players and newcomers are seeking funding to conduct research & development and clinical testing of the NIPT techniques.
 

Private organizations and government are actively looking for research institutes and new firms to develop novel testing procedures to detect any genetic disorders through NIPT.
 

Stakeholders, through this research, can get data on the number of NIPT tests performed in the U.S. with seven years forecast, along with assessment of market potential and opportunities for the testing. The document also highlights the regulatory frameworks of the economy, coupled with reimbursement policies, recent industry developments, distribution, and exclusive and licensing agreement.
 

Major companies defining the competitive landscape of U.S. non-invasive prenatal testing market sphere are Integrated Genetics (LabCorp), Ariosa Diagnostics (Roche), Agilent Technologies Inc., Invitae Corporation, Yourgene Health, and PerkinElmer among others.